VEGFA and hemolytic-uremic syndrome: This suggests that Stx2 is affecting podocyte VEGF-A transcription, not just VEGF-A protein translation, as expected given its known ribotoxicity.20 Reduced podocyte VEGF-A production was also detectable by day 4, suggesting this is also an early event in the STEC-HUS process (Figure S4).